Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2026-01-21 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司关于股份回购实施结果暨股份变动的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the implementation results of a share repurchase program by 奥锐特药业股份有限公司. It details the number of shares repurchased, the price range, the purpose of the repurchase (conversion of convertible bonds), approvals by the board, and related disclosures about shareholding changes and management transactions. The document does not contain financial statements or comprehensive financial analysis but focuses on the share buyback activity and related shareholding changes. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2026-01-21 Chinese
奥锐特药业股份有限公司关于调整回购价格上限的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from a company's board regarding the adjustment of the upper limit price for a share repurchase program. It details the board meeting decision, the background of the repurchase plan, progress to date, and the rationale for adjusting the repurchase price ceiling. It does not contain financial statements or detailed financial analysis but focuses on the update of the share repurchase terms. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company announcements about share buybacks or sales of its own shares.
2026-01-12 Chinese
奥锐特药业股份有限公司关于可转债转股结果暨股份变动公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the results of convertible bond conversions and related changes in share capital. It includes details about the issuance, listing, and conversion of convertible bonds, cumulative and quarterly conversion figures, and changes in share capital structure. The document is relatively short (2007 characters) and focuses on reporting the conversion results and shareholding changes rather than providing a full financial report or detailed analysis. This fits the category of a Share Issue/Capital Change announcement, as it deals with convertible bond conversions impacting the company's capital structure.
2026-01-05 Chinese
奥锐特药业股份有限公司关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the progress of the company's share repurchase program. It details the number of shares repurchased, the price range, the total amount spent, and references previous announcements and regulatory compliance. It does not contain financial statements or comprehensive financial data but rather updates on the share buyback activity. The document length is short (1827 characters) and focuses on the repurchase progress, fitting the description of a Transaction in Own Shares (POS) filing rather than a full financial report or other categories.
2026-01-04 Chinese
国泰海通证券股份有限公司关于奥锐特药业股份有限公司向不特定对象发行可转换公司债券第三次临时受托管理事务报告
Capital/Financing Update Classification · 82% confidence The document contains detailed terms of a new bond issuance (issue date, volume, coupon rates/tranches, maturity, credit ratings, yield calculation formulas, underwriters, subscription criteria). It is clearly a financing activity announcement rather than a simple regulatory notice or interest‐rate adjustment. Therefore it falls under Capital/Financing Update (CAP).
2025-12-30 Chinese
国浩律师（杭州）事务所关于奥锐特药业股份有限公司2022年限制性股票激励计划部分限制性股票回购注销实施的法律意见书
Regulatory Filings Classification · 75% confidence The document is a legal opinion letter (“法律意见书”) provided by a law firm concerning the repurchase and cancellation of restricted shares under the company’s 2022 stock incentive plan. It is essentially an attestation/certification by the law firm rather than the primary transaction notice itself. Under the certification rule, such legal opinion letters and attestations are classified as Regulatory Filings (RNS), not as the underlying financial or transaction report.
2025-12-30 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.